{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:09:47Z","timestamp":1779358187102,"version":"3.51.4"},"reference-count":63,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Metastatic pancreatic ductal adenocarcinoma (PDAC) is typically treated with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP), but the choice between regimens remains largely empirical. This narrative review summarizes biomarkers with potential to inform first-line selection in metastatic PDAC, emphasizing genomic and transcriptomic correlates of differential benefit. Recent head-to-head trials, particularly Pancreatic Adenocarcinoma Signature Stratification for Treatment (PASS-01) and GENERATE (Japan Clinical Oncology Group [JCOG] 1611), indicate that modified FOLFIRINOX (mFOLFIRINOX) is not uniformly superior to GnP, strengthening the rationale for biomarker-guided selection. The strongest evidence favoring platinum-based\/FOLFIRINOX strategies involves homologous recombination repair deficiency (HRD), especially alterations in germline breast cancer gene 1\/2 (BRCA1\/2) or partner and localizer of BRCA2 (PALB2), as well as broader genomic scar signatures. Transcriptomic subtype and GATA-binding protein 6 (GATA6) expression are promising but remain unsettled because retrospective data favor classical\/GATA6-high disease for FOLFIRINOX, whereas PASS-01 suggested better outcomes with GnP in classical tumors. Candidate biomarkers favoring GnP include high human equilibrative nucleoside transporter 1 (hENT1), low class III \u03b2-tubulin (TUBB3) expression, and exploratory phosphatidylinositol 3-kinase (PI3K)\/KIT\/NOTCH pathway mutation signals. Comprehensive molecular profiling also identifies actionable alterations that may redirect patients to targeted therapy or clinical trials rather than standard chemotherapy alone. Importantly, no biomarker has yet been prospectively validated in a biomarker-stratified randomized trial with regimen selection as the primary endpoint; all biomarker-regimen associations described in this review should therefore be considered hypothesis-generating rather than practice-defining. Nevertheless, the convergence of genomic, transcriptomic, and organoid-based approaches makes biologically informed first-line selection increasingly feasible in metastatic PDAC.<\/jats:p>","DOI":"10.3390\/cancers18101664","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:29:58Z","timestamp":1779355798000},"page":"1664","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic Biomarkers for First-Line Treatment Selection in Metastatic Pancreatic Ductal Adenocarcinoma: A Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0113-4560","authenticated-orcid":false,"given":"Anushareddy","family":"Muddasani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abdelnoor","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Zagazig University, Zazazig 44519, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-5162","authenticated-orcid":false,"given":"Ashish","family":"Manne","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic Cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1097\/MPA.0000000000002489","article-title":"Factors Driving Pancreatic Cancer Survival Rates","volume":"54","author":"Rahib","year":"2025","journal-title":"Pancreas"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus Nab-Paclitaxel and Gemcitabine in Treatment-Naive Patients with Metastatic Pancreatic Ductal Adenocarcinoma (NAPOLI 3): A Randomised, Open-Label, Phase 3 Trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall Survival in Patients with Pancreatic Cancer Receiving Matched Therapies Following Molecular Profiling: A Retrospective Analysis of the Know Your Tumor Registry Trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1038\/s41467-025-60808-z","article-title":"Whole Genome and Transcriptome Profiling in Advanced Pancreatic Cancer Patients on the COMPASS Trial","volume":"16","author":"Knox","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO-25-00436","article-title":"PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine\/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer","volume":"43","author":"Knox","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.24.00936","article-title":"Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II\/III Trial","volume":"43","author":"Ohba","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer: A Systematic Review and Bayesian Network Meta-Analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2216199","DOI":"10.1001\/jamanetworkopen.2022.16199","article-title":"Comparison of FOLFIRINOX vs. Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma","volume":"5","author":"Lawrence","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Shalaby, A., Sadri, N., and Xue, Y. (2025). Molecular Pathology of Pancreatic Ductal Adenocarcinoma. Cancers, 17.","DOI":"10.20944\/preprints202509.2579.v1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1158\/1078-0432.CCR-24-1164","article-title":"Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e001925","DOI":"10.1136\/bmjgast-2025-001925","article-title":"Actionable Mutations in Pancreatic Cancer: Where Targeted Therapies Are Making a Difference","volume":"12","author":"Fivaz","year":"2025","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic Analyses Identify Molecular Subtypes of Pancreatic Cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual Microdissection Identifies Distinct Tumor- and Stroma-Specific Subtypes of Pancreatic Ductal Adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.trsl.2024.08.002","article-title":"Transcriptome-Based Classification to Predict FOLFIRINOX Response in a Real-World Metastatic Pancreatic Cancer Cohort","volume":"273","author":"Lansbergen","year":"2024","journal-title":"Transl. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2500197","DOI":"10.1200\/PO-25-00197","article-title":"Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma","volume":"9","author":"Wenric","year":"2025","journal-title":"JCO Precis Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum Response Characteristics of Patients with Pancreatic Ductal Adenocarcinoma and a Germline BRCA1, BRCA2 or PALB2 Mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/oncolo\/oyad178","article-title":"A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer","volume":"28","author":"Chen","year":"2023","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17588359221083050","DOI":"10.1177\/17588359221083050","article-title":"Platinum-Based Chemotherapy for Pancreatic Cancer: Impact of Mutations in the Homologous Recombination Repair and Fanconi Anemia Genes","volume":"14","author":"Emelyanova","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.21037\/jgo.2018.03.11","article-title":"Exceptional Response to FOLFIRINOX in a Patient with Pancreatic Cancer and a Germline RAD51C Mutation","volume":"9","author":"Palacio","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2023.41.16_suppl.4137","article-title":"Retrospective Evaluation of the Value of DNA Damage Repair Gene Signature in Response to Platinum-Based Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma","volume":"41","author":"Tian","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41591-026-04299-5","article-title":"Pembrolizumab and Olaparib in Homologous-Recombination-Deficient Metastatic Pancreatic Cancer: The Phase 2 POLAR Trial","volume":"32","author":"Park","year":"2026","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/cas.70351","article-title":"FOLFIRINOX vs. Gemcitabine\/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C- CAT Database Study","volume":"117","author":"Mizuno","year":"2026","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Li, W., Leibowitz, J.A., Wang, S., Walker, L., Xu, C., Chen, K.-T., Schrock, A.B., Hughes, J., Patel, N., and Elvin, J.A. (2025). Analytical Validation of a Homologous Recombination Deficiency Signature (HRDsig) in Pan-Tumor Tissue Samples. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0336940"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2024.42.16_suppl.4150","article-title":"GATA6 Expression in Advanced Pancreatic Ductal Adenocarcinoma (PDAC) as a Prognostic and Predictive Biomarker in the Canadian COMPASS Trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS","volume":"42","author":"Salvatore","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2453588","DOI":"10.1001\/jamanetworkopen.2024.53588","article-title":"KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma","volume":"8","author":"Norton","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2023.41.16_suppl.4150","article-title":"KRAS G12C-Mutated Pancreatic Cancer: Clinical Outcomes Based on Chemotherapeutic Regimen","volume":"41","author":"Ciner","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-Selective, Noncovalent Tri-Complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Randazzo, O., Papini, F., Mantini, G., Gregori, A., Parrino, B., Liu, D.S.K., Cascioferro, S., Carbone, D., Peters, G.J., and Frampton, A.E. (2020). \u201cOpen Sesame?\u201d: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing Its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. Cancers, 12.","DOI":"10.3390\/cancers12113206"},{"key":"ref_39","first-page":"4349","article-title":"Functional Nucleoside Transporters Are Required for Gemcitabine Influx and Manifestation of Toxicity in Cancer Cell Lines","volume":"58","author":"Mackey","year":"1998","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1158\/1078-0432.CCR-22-2576","article-title":"hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma","volume":"28","author":"Perera","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pan.2024.01.009","article-title":"The Prognostic and Predictive Role of Class III \u03b2-Tubulin and hENT1 Expression in Patients with Advanced Pancreatic Ductal Adenocarcinoma","volume":"24","author":"Sahin","year":"2024","journal-title":"Pancreatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","article-title":"Is Class III \u03b2-Tubulin a Predictive Factor in Patients Receiving Tubulin-Binding Agents?","volume":"9","author":"Dumontet","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12902","DOI":"10.1074\/jbc.M414477200","article-title":"\u03b2III-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability","volume":"280","author":"Kamath","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.humpath.2018.01.009","article-title":"The Absence of Class III \u03b2-Tubulin Is Predictive of a Favorable Response to Nab-Paclitaxel and Gemcitabine in Patients with Unresectable Pancreatic Ductal Adenocarcinoma","volume":"74","author":"Kato","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MPA.0000000000002032","article-title":"Class III \u03b2-Tubulin Expression Is of Value in Selecting Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer","volume":"51","author":"Kato","year":"2022","journal-title":"Pancreas"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CAD.0b013e32830f9046","article-title":"Improved Effectiveness of Nanoparticle Albumin-Bound (Nab) Paclitaxel versus Polysorbate-Based Docetaxel in Multiple Xenografts as a Function of HER2 and SPARC Status","volume":"19","author":"Desai","year":"2008","journal-title":"Anti Cancer Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"Nab-Paclitaxel Mechanisms of Action and Delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Control. Rel."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10555-013-9439-3","article-title":"Stromal Expression of SPARC in Pancreatic Adenocarcinoma","volume":"32","author":"Neuzillet","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1158\/1078-0432.CCR-14-3222","article-title":"SPARC Expression Did Not Predict Efficacy of Nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial","volume":"21","author":"Hidalgo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21953","DOI":"10.1038\/s41598-024-73020-8","article-title":"Mcl-1 Expression Is a Predictive Marker of Response to Gemcitabine plus Nab-Paclitaxel for Metastatic Pancreatic Cancer","volume":"14","author":"Urabe","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_51","unstructured":"(2023). Notch Signaling Pathway in Pancreatic Tumorigenesis. Advances in Cancer Research, Elsevier."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Paredes De La Fuente, R., Sucre, S., Ponce, C., Rattani, A.A.A., and Peters, M.L.B. (2024). Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel. Cancers, 16.","DOI":"10.3390\/cancers16152734"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-22-3089","article-title":"Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma","volume":"29","author":"Ecker","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Button, J., Kanu, E., Agritelley, E., Dickey, E.M., Diskin, B., Sarkari, A., Zaman, U., Sharanappa, R., Kim, A., and Marin-Guerra, V. (2025). SMAD4 Alterations Are a Predictive Biomarker to Guide First-Line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer: A Multicenter, Retrospective Cohort Study. Ann. Surg.","DOI":"10.1097\/SLA.0000000000006966"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hsieh, Y.-Y., Liu, T.-P., Chou, C.-J., Chen, H.-Y., Lee, K.-H., and Yang, P.-M. (2019). Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma. Genes, 10.","DOI":"10.3390\/genes10100766"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.annonc.2020.10.601","article-title":"A Transcriptomic Signature to Predict Adjuvant Gemcitabine Sensitivity in Pancreatic Adenocarcinoma","volume":"32","author":"Nicolle","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/ueg2.70124","article-title":"Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures","volume":"13","author":"Chanez","year":"2025","journal-title":"UEG J."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kirchweger, P., Kupferthaler, A., Burghofer, J., Webersinke, G., Jukic, E., Schwendinger, S., Wundsam, H., Biebl, M., Petzer, A., and Rumpold, H. (2022). Prediction of Response to Systemic Treatment by Kinetics of Circulating Tumor DNA in Metastatic Pancreatic Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.902177"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1158\/1078-0432.CCR-25-0758","article-title":"The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST","volume":"31","author":"Steiniche","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.gastro.2024.05.032","article-title":"Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer","volume":"167","author":"Cartry","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41591-026-04327-4","article-title":"Elraglusib and Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Phase 2 Trial","volume":"32","author":"Mahalingam","year":"2026","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.dld.2025.11.007","article-title":"A Phase III Randomized Clinical Trial of Gemcitabine and Nab-Paclitaxel as Switch Maintenance versus Continuation of Modified FOLFIRINOX as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer: The PANThEON Study","volume":"57","author":"Sciortino","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, B., Zhang, Q., Castaneda, C., and Cook, S. (2024). Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102175"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1664\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:47:45Z","timestamp":1779356865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101664"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101664","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}